Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Global Cancer Antibody Drug Conjugates Market Landscape 2024-2030 Featuring Biocytogen, Merck, AstraZeneca, Pfizer, Daiichi Sankyo, and ADC Therapeutics Research and Markets Mon, Mar 24, 2025, 5: ...

Days after AstraZeneca set out how new ... while in December 2023 Pfizer handed over $53 million for a mesothelin-targeted antibody-drug conjugate.

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection ... for RSV prevention reach the market. Pfizer is currently leading the race ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a Strong Buy despite market doubts.

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC ... compete with molecules from AbbVie and Pfizer. The Anglo-Swedish drugmaker is a leading ...

The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...